Serum chemical biomarkers of cardiac injury for nonclinical safety testing.
There has been a substantial increase in the number and efficacy of laboratory biomarkers for the evaluation of human cardiac injury over the last decade. The advantages of these over traditional laboratory tests have encouraged adoption of comparable markers in nonclinical studies for cardiac injury assessment. Of particular interest are markers that are not only more sensitive and/or specific than traditional parameters for cardiac injury, but also those that may directly bridge human and laboratory animal safety testing. However, a majority of recently developed markers are quantified through antibody-based assays, and cross-reactivity with the comparable analyte in nonhuman samples is difficult to predict and often species-variable. The utility of these novel biomarkers thus, depends upon adequate assay validation with each laboratory species of interest. In contrast, traditional laboratory parameters of cardiac injury lack the properties of an ideal biomarker, but are well established and have an extensive database in nonclinical safety assessment. The current status and utility of both recently developed and traditional biomarkers of cardiac injury in nonclinical testing, and considerations for validation of novel biomarkers of cardiac injury are reviewed.
Walker
Dana B
DB
Wyeth Research Laboratories, Chazy, New York 12901, USA. Walkerd4@wyeth.com
D000818:Animals; D000830:Animals, Laboratory; D015415:Biomarkers / Q000097:blood; D003935:Diagnostic Techniques, Cardiovascular; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D064420:Drug-Related Side Effects and Adverse Reactions; D006331:Heart Diseases / Q000097:blood / Q000139:chemically induced / Q000175:diagnosis*; D004364:Pharmaceutical Preparations / Q000145:classification; D018675:Toxicity Tests / Q000379:methods*
D015415:Biomarkers; D004364:Pharmaceutical Preparations